The sodium-iodine symporter and the proton-pump inhibitors in-related to the side effects of-the treatment of thyroid cancer with iodine-131

Hellenic Journal of Nuclear Medicine

Volumn 10, Issue 1, 2007, Pages 2-5

  Sfakianakis, George ^a   Sfakianaki, Efrosyni ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

131I biologic properties; Proton pump inhibitors; Sodium iodine symporter; Thyroid cancer treatment

Indexed keywords

COTRANSPORTER; ESOMEPRAZOLE; IODINE 131; PANTOPRAZOLE; PROTON PUMP INHIBITOR; SODIUM IODINE SYMPORTER; UNCLASSIFIED DRUG;

ANOREXIA; BIOLOGICAL ACTIVITY; BREAST CELL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; EDITORIAL; GASTRITIS; HUMAN; LUNG ALVEOLUS EPITHELIUM; MAMMARY GLAND; MEGALOBLASTIC ANEMIA; NONHUMAN; PASSIVE TRANSPORT; PROTEIN FUNCTION; SALIVARY GLAND; STOMACH ACID SECRETION; STOMACH MUCOSA; STOMACH PARIETAL CELL; THYROID CANCER; THYROID CELL; THYROID SCINTISCANNING; WHOLE BODY SCINTISCANNING; XEROSTOMIA;

ANIMALS; HUMANS; IODINE RADIOISOTOPES; MODELS, BIOLOGICAL; PROTON PUMPS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOPHARMACEUTICALS; SYMPORTERS; THYROID GLAND; THYROID NEOPLASMS;

EID: 34247897058     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Johansson L, Leide-Svegborn S, Matisson S, et al. Biokinetics of iodine in man: Refinement of current ICRP dosimetry models. Cancer Biother and Radiopharmaceuticals 2003; 18: 445-450.
2. Bruno R, Giannasio P, Ronga G, et al. Sodium iodide symporter expression and radioiodine distribution in extrathyroid tissues. J Endocrinol Invest 2004; 27: 1010-1014.
3. Josefsson M, Grunditz T, Westrom B et al. Sodium/iodide - symporter. Distribution in different mammals and role in entero-thyroid circulation of iodide. Acta Physiol Scand 2002; 175: 129-137.
4. Dohan O, DeLaViega A, Paroder V, et al. The sodium/iodide symporter (NIS): Characterization, regulation, and medical significance. Endocr Rev 2003; 24: 48-77.
5. Brockmann H, Wilhelm K, Joe A, et al. Nasolacrimal drainage obstruction after radioiodine therapy: Case report and a review of the literature. Clin Nucl Med 2005; 30: 543-545.
6. 123I uptake by intrathoracic stomach. Clin Nucl Med 2005; 30: 42.
7. Wolfe M. Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders. UpToDate - www.uptodate.com 2006; 1-14.
8. Dadachova E, Carrasco N. The Na+/I-symporter (NIS): Imaging and therapeutic applications. Sem Nucl Med XXXIV 2004; 1: 23-31.
9. Chung JK. Sodium iodide symporter: Its role in Nuclear Medicine. J Nucl Med 2002; 43: 1188-1200.
10. Lacroix L, Mian C, Caillou B, et al. Na+/I-symporter and pendred syndrome gene and protein expressions in human extra-thyroidal tissues. Eur J Endocr 2001; 144: 297-302.
11. De Groef B, Decallonne BR, Van der Geyten S, et al. Perchlorate versus other environmental sodium/iodide symporter inhibitors: Potential thyroid-related health effects. Eur J Endocr 2006; 155: 17-25.
12. Josefsson M, Evilevitch L, Westrom B, et al. Sodium-iodide symporter mediates iodide secretion in rat gastro mucosa in vitro. Exp Biol Med 2006; 231: 277-281.